AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in AZN shares today? Let’s find out!

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.

In the latest trading session, Astrazeneca (AZN) closed at $166.68, marking a +2.87% move from the previous day. This move outpaced the S&P 500's daily gain of 0.33%. Elsewhere, the Dow saw an upswing ...

AstraZeneca reports 9M and third-quarter results October 30, 2026. AstraZeneca stock costs EUR 150.53 on October 21, 2026 at ...

AstraZeneca Plc(NYSE: AZN) reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term survival advantages in lung cancer treatments alongside mixed findings in ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

AstraZeneca remains a long-term Buy despite recent setbacks, underpinned by robust product and pipeline strength. Click here ...

Markets Insider reported on October 26, 2026, that Barclays analyst James Gordon maintained a Buy rating on AstraZeneca and ...

AstraZeneca (AZN) stock came under pressure on Sept. 29 after the pharma giant announced a massive $2 billion investment in Summit Therapeutics (SMMT). As investors responded to the disclosure, AZN ...